Acura Pharmaceuticals, Inc. is a ground-breaking drug delivery company that focuses on developing and commercializing technologies and products aimed at ensuring the safe use of medications in the United States. Among its notable products are Oxaydo tablets, which are designated as Schedule II narcotics for the treatment of both acute and chronic moderate to severe pain, as well as Nexafed products, which are pseudoephedrine and acetaminophen tablets that aid in decongesting the nose in a variety of non-prescription and prescription cold, sinus, and allergy medications. The company also has six additional opioid products in varying stages of development. Acura Pharmaceuticals, Inc. has inked collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to produce and market Oxaydo products globally, and a development and commercialization agreement with Abuse Deterrent Pharma, LLC to create LTX-03, an instant-release tablet that utilizes LIMITx technology. Since its founding in 1935, Acura Pharmaceuticals, Inc. has been headquartered in Palatine, Illinois.